Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)
Close on Nov 18, 2026Market cap $528.94MP/E –Yield –
Myriad Genetics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Myriad Genetics's revenue for the twelve months ending Jun 30, 2026 was $806.60M, down 3.2% year over year. For fiscal 2025 it was $824.50M, down 1.6% from the year before. Over ten years it grew 0.6% a year on average. The highest annual figure on record is $851.10M in fiscal 2019.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $824.50M | -1.6% |
| FY2024 | Dec 31, 2024 | $837.60M | +11.2% |
| FY2023 | Dec 31, 2023 | $753.20M | +11.0% |
| FY2022 | Dec 31, 2022 | $678.40M | +6.2% |
| FY2020 | Jun 30, 2020 | $638.60M | -25.0% |
| FY2019 | Jun 30, 2019 | $851.10M | +14.4% |
| FY2018 | Jun 30, 2018 | $743.70M | +2.1% |
| FY2017 | Jun 30, 2017 | $728.70M | -1.6% |
| FY2016 | Jun 30, 2016 | $740.50M | +2.5% |
| FY2015 | Jun 30, 2015 | $722.50M | -7.2% |
| FY2014 | Jun 30, 2014 | $778.20M | +26.9% |
| FY2013 | Jun 30, 2013 | $613.20M | +23.6% |
| FY2012 | Jun 30, 2012 | $496.01M | +23.4% |
| FY2011 | Jun 30, 2011 | $402.08M | +10.9% |
| FY2010 | Jun 30, 2010 | $362.65M | +11.1% |
| FY2009 | Jun 30, 2009 | $326.53M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $190.70M | -10.5% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $200.40M | +2.3% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $209.80M | -0.4% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $205.70M | -3.6% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $213.10M | +0.8% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $195.90M | -3.1% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $210.60M | +7.1% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $213.30M | +11.2% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $211.50M | +15.3% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $202.20M | +11.6% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $196.60M | +10.6% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $191.90M | +22.7% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $183.50M | +2.3% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $181.20M | +9.9% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $177.80M | +90.8% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $156.40M | -4.6% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $179.30M | -8.1% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $164.90M | -11.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $93.20M | -56.7% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $164.00M | -24.3% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $195.10M | -10.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $186.30M | -7.9% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $215.40M | +11.1% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $216.60M | +18.3% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $216.80M | +15.4% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $202.30M | +13.1% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $193.90M | -2.9% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $183.10M | -6.0% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $187.90M | -4.5% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $178.80M | -0.1% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $199.60M | +15.3% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $194.70M | +2.2% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $196.70M | +1.8% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $178.90M | -2.5% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $173.10M | -8.6% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $190.50M | +5.8% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $193.30M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $183.50M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $189.30M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $180.00M | – |
See a number that looks wrong?